Zevra Therapeutics

Zevra Therapeutics, Inc. is a biopharmaceutical company focused on the development of treatments for rare diseases. Leveraging a unique data-driven approach to clinical, regulatory, and commercial strategies, the company is addressing complex drug development challenges to deliver urgently needed therapies to patients. Arimoclomol, Zevra's orally administered first-in-class investigational candidate for the treatment of Niemann-Pick type C ("NPC"), has been granted Orphan Drug Designation, Fast Track Designation, and Rare Pediatric Disease Designation by the U.S. Food and Drug Administration ("FDA") and the European Medicines Agency ("EMA"). KP1077 is Zevra’s lead clinical candidate being developed for the treatment of Idiopathic Hypersomnia ("IH") and narcolepsy.